Skip to main content
. 2024 Jul 31;11(3):13–22. doi: 10.15586/jkcvhl.v11i3.319

Table 3:

Treatment characteristics of patients with mRCC who did or did not develop thromboembolic complications during treatment.

Treatment n (%) TE (N=17) Non-TE (N=317) p-value
ICI only 3 (18) 34 (11) 0.42
TKI only 5 (29) 222 (70) 0.0009
TKI-ICI 6 (35) 24 (7) 0.0019
Other 3 (18) 37 (12) 0.41